These findings demonstrated that concomitantly administered etanercept and tacrolimus exerted additive and/or synergistic inhibitory effects on the progression of arthritis, largely via suppression of MMP-3 production, CD11bhigh OCP mobilization, and osteoclast differentiation but did not affect ADA production. The gene discussed is ADA; the disease is arthritic joint disease.